Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

  1. Spelman, T.
  2. Herring, W.L.
  3. Zhang, Y.
  4. Tempest, M.
  5. Pearson, I.
  6. Freudensprung, U.
  7. Acosta, C.
  8. Dort, T.
  9. Hyde, R.
  10. Havrdova, E.
  11. Horakova, D.
  12. Trojano, M.
  13. De Luca, G.
  14. Lugaresi, A.
  15. Izquierdo, G.
  16. Grammond, P.
  17. Duquette, P.
  18. Alroughani, R.
  19. Pucci, E.
  20. Granella, F.
  21. Lechner-Scott, J.
  22. Sola, P.
  23. Ferraro, D.
  24. Grand’Maison, F.
  25. Terzi, M.
  26. Rozsa, C.
  27. Boz, C.
  28. Hupperts, R.
  29. Van Pesch, V.
  30. Oreja-Guevara, C.
  31. van der Walt, A.
  32. Jokubaitis, V.G.
  33. Kalincik, T.
  34. Butzkueven, H.
  35. Horakova, D.
  36. Trojano, M.
  37. Luca, G.
  38. Lugaresi, A.
  39. Izquierdo, G.
  40. Pucci, E.
  41. Lechner-Scott, J.
  42. Sola, P.
  43. Butzkueven, H.
  44. Erakutsi egile guztiak +
Aldizkaria:
PharmacoEconomics

ISSN: 1179-2027,  1170-7690

Argitalpen urtea: 2022

Alea: 40

Zenbakia: 3

Orrialdeak: 323-339

Mota: Artikulua

DOI: 10.1007/S40273-021-01106-6 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus